Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services

作者：Trajman Anete^*; Bastos Mayara Li**oa; Belo Marcia; Calaca Janaina; Gaspar Julia; dos Santos Alexandre Martins; dos Santos Camila Martins; Brito Raquel Trindade; Wells William A; Cobelens Frank G; Vassall Anna; Gomez Gabriela B

来源：BMC Health Services Research, 2016, 16(1): 27.

DOI：10.1186/s12913-016-1269-x

• Tuberculosis
• Antitubercular agents
• Brazil
• Directly observed therapy
• Health care costs

Background: Shortened treatment regimens for tuberculosis are under development to improve treatment outcomes and reduce costs. We estimated potential savings from a societal perspective in Brazil following the introduction of a hypothetical four-month regimen for tuberculosis treatment.
Methods: Data were gathered in ten randomly selected health facilities in Rio de Janeiro. Health service costs were estimated using an ingredient approach. Patient costs were estimated from a questionnaire administered to 126 patients. Costs per visits and per case treated were analysed according to the type of therapy: self-administered treatment (SAT), community-and facility-directly observed treatment (community-DOT, facility-DOT).
Results: During the last 2 months of treatment, the largest savings could be expected for community-DOT; on average USD 17,351-18,203 and USD 43,660-45,856 (bottom-up and top-down estimates) per clinic. Savings to patients could also be expected as the median (interquartile range) patient-related costs during the two last months were USD 108 (13-291), USD 93 (36-239) and USD 11 (7-126), respectively for SAT, facility-DOT and community-DOT.
Conclusion: Introducing a four-month regimen may result in significant cost savings for both the health service and patients, especially the poorest. In particular, a community-DOT strategy, including treatment at home, could maximise health services savings while limiting patient costs. Our cost estimates are likely to be conservative because a 4-month regimen could hypothetically increase the proportion of patients cured by reducing the number of patients defaulting and we did not include the possible cost benefits from the subsequent prevention of costs due to downstream transmission averted and rapid clinical improvement with less side effects in the last two months.

• 出版日期2016-1-22